2024
Pilot study of a novel, alternative subdermal scapular insertion site for the etonogestrel contraceptive implant
Clure C, Sheeder J, Lazorwitz A. Pilot study of a novel, alternative subdermal scapular insertion site for the etonogestrel contraceptive implant. Contraception 2024, 135: 110442. PMID: 38552822, DOI: 10.1016/j.contraception.2024.110442.Peer-Reviewed Original ResearchEtonogestrel contraceptive implantContraceptive implantsMedian body mass indexMedian pain scoreBody mass indexTime pointsBleeding side effectsEtonogestrel implantImplant placementReproductive-age femalesENG implantSite painPain scoresMedian ageInsertion siteEtonogestrelMass indexPilot studyPatient populationInferior edgeSide effectsPharmacokineticsImplantationWeeksSerum
2022
P077Pilot study on a novel, alternative subdermal scapular insertion site for the etonogestrel contraceptive implant
Clure C, Sheeder J, Lazorwitz A. P077Pilot study on a novel, alternative subdermal scapular insertion site for the etonogestrel contraceptive implant. Contraception 2022, 116: 91. DOI: 10.1016/j.contraception.2022.09.101.Peer-Reviewed Original ResearchEtonogestrel contraceptive implantContraceptive implantsENG implantENG levelsSide effectsMedian pain scoreTime pointsReproductive-aged womenScapular insertionPain scoresSite painMedian ageMedian BMIImplant useInferior edgeInsertion siteWeek twoYears of useFirst weekPilot studyImplant usersPharmacokineticsImplantsFirst yearWeeksP079Etonogestrel contraceptive implant users can experience breakthrough ovulation with only two weeks of exposure to a strong cyp3a inducer
Lazorwitz A, Teal S, Sheeder J. P079Etonogestrel contraceptive implant users can experience breakthrough ovulation with only two weeks of exposure to a strong cyp3a inducer. Contraception 2022, 116: 92. DOI: 10.1016/j.contraception.2022.09.103.Peer-Reviewed Original ResearchStrong CYP3A inducersBreakthrough ovulationCYP3A inducersE2 concentrationsP4 concentrationsMedian ageOvulation suppressionImplant usersPg/Baseline serum concentrationsContraceptive implant usersEtonogestrel implant usersSerum E2 concentrationsParticipants' median ageSerum P4 concentrationsENG implant usersDrug-drug interactionsRifampin exposureMedian durationENG implantMedian BMIEndogenous estradiolSerum concentrationsSurrogate biomarkerWeeks of exposure